Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

NCT02855944

III

Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

View Drugs

Colorado, Georgia

Drug(s) in Trial	Other Drug Names	Main Known Action
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

NCT03398655

III

Platinum resistant ovarian cancer

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

View Drugs

Arizona, California, Connecticut, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Ofranergene Obadenovec	VB-111	Endothelin promoter-apoptotic receptor gene therapy
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02091141

IIa

Advanced solid tumors with ALK mutations or high TMB

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

View Drugs

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Alectinib	ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802	ALK kinase inhibitor
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells

NCT02584478

IIa

Recurrent ovarian cancer

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

View Drugs

California, Florida, Louisiana, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Anlotinib	AL3818	VEGFR2/3 kinase inhibitor
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02419417

IIa

Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

View Drugs

California, Colorado, Massachusetts, Oregon, Pennsylvania, South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986158	BET inhibitor BMS-986158	BET inhibitor
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT02502266

II/III

Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

View Drugs

Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

NCT02272998

Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations

Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

View Drugs

Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
Ponatinib	multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534	Multi-targeted kinase inhibitor

NCT02079740

Advanced solid tumors with KRAS or NRAS mutations (in expansion)

An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors

View Drugs

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Navitoclax	Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263	Bcl-2, Bcl-XL, and Bcl-w inhibitor
Trametinib	TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist	MEK1/2 inhibitor

NCT01037790

Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

View Drugs

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Palbociclib	Ibrance, PD0332991, PD-0332991	CDK4/6 inhibitor

NCT01953926

Advanced solid tumors with activating HER2 mutations

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.

View Drugs

Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Neratinib	HKI-272, PD272	EGFR, HER2, HER4 kinase inhibitor

NCT02203513

Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

View Drugs

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Prexasertib	checkpoint kinase 1 inhibitor LY2606368, LY2606368	Chk1/2 inhibitor

NCT02312245

Platinum resistant or refractory ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

View Drugs

Arizona, Florida, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor

NCT02568267

Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

View Drugs

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101	ALK, TRK, ROS1 kinase inhibitor

NCT02485990

Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)

An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

View Drugs

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

NCT02693535

Ovarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high)

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

View Drugs

Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Cetuximab	Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225	EGFR antagonist
Cobimetinib	Cotellic, GDC-0973, XL518	MEK1 inhibitor
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor
Dasatinib	BMS-354825, Sprycel	SRC and bcr-abl kinase inhibitor
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Palbociclib	Ibrance, PD0332991, PD-0332991	CDK4/6 inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
Temsirolimus	CCI-779, Torisel	mTOR inhibitor
Trastuzumab	HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin	HER2 antagonist
Vemurafenib	RO5185426, PLX4032, Zelboraf	BRAF kinase inhibitor

NCT02465060

Advanced solid tumors with alterations in AKT, BRAF, cKIT, CDK4 AMP, CDK6 AMP, EGFR, ERBB2 AMP, FGFR1-4, FGFR1-4 AMP, MET, MET AMP, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2

Molecular Analysis for Therapy Choice (MATCH)

View Drugs

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

Drug(s) in Trial	Other Drug Names	Main Known Action
Afatinib	BIBW 2992 MA2, Gilotrif, Afatinib dimaleate	EGFR, HER2, HER4 kinase inhibitor
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor
Erdafitinib	pan-FGFR tyrosine kinase inhibitor JNJ-42756493	pan-FGFR kinase inhibitor
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor
Larotrectinib	Trk inhibitor LOXO-101	Pan-Trk kinase inhibitor
Osimertinib	Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib	EGFR kinase inhibitor
Palbociclib	Ibrance, PD0332991, PD-0332991	CDK4/6 inhibitor
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor
Sapanisertib	TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128	TORC1/2 kinase inhibitor
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
Trastuzumab	HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin	HER2 antagonist
Trastuzumab emtansine	ado trastuzumab emtansine, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1 immunoconjugate	ADC: anti-HER2 + microtubule destabilizer (DM1)
Ulixertinib	BVD-523, ERK inhibitor BVD-523	ERK inhibitor
Vismodegib	Hedgehog antagonist GDC-0449, Erivedge, GDC-0449	Smoothened antagonist

NCT01827384

Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53

Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors

View Drugs

Colorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Everolimus	Zortress, RAD001, Certican, Afinitor	mTOR inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent
Trametinib	TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist	MEK1/2 inhibitor
Veliparib	ABT-888	PARP inhibitor

NCT02554812

Advanced solid tumors (in ovarian expansion)

A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

View Drugs

California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
PD-0360324	anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324	CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600	anti-OX40 antibody PF-04518600	Stimulates OX40 to increase T cell activation and immune response

NCT02832167

Advanced solid tumors

An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

View Drugs

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT02628067

Advanced solid tumors with high MSI

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

View Drugs

California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02576444

Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

View Drugs

Connecticut, Massachusetts, Ohio, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Capivasertib	Akt inhibitor AZD5363	pan-AKT inhibitor
Ceralasertib	AZD6738	ATR kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

NCT02571725

Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer

View Drugs

Florida, New Mexico, Ohio, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

NCT02873962

Platinum resistant or partially sensitive ovarian cancer

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

View Drugs

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

NCT02873975

Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations

A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

View Drugs

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Prexasertib	checkpoint kinase 1 inhibitor LY2606368, LY2606368	Chk1/2 inhibitor

NCT01851369

Advanced solid tumors and granulosa cell ovarian cancer (in expansion)

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

View Drugs

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
methoxyamine	TRC102	Base excision repair inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent

NCT02901899

Platinum resistant ovarian cancer

An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

View Drugs

Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
Guadecitabine	DNA methyltransferase inhibitor SGI-110, SGI-110	DNA methylation inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02364713

Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)

A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

View Drugs

Arizona, Florida, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis

NCT02834013

Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

View Drugs

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT02900560

Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)

Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

View Drugs

California, Maryland, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Oral Azacitidine	CC-486	DNA methylation inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02843165

Advanced solid tumors with lesion treatable with radiation therapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

View Drugs

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Radiation Therapy	Radiotherapy, Irradiation

NCT03026062

Platinum resistant or refractory ovarian cancer

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

View Drugs

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

NCT03093155

Platinum resistant, refractory or persistent ovarian cancer

A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

View Drugs

Connecticut, Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Ixabepilone	Ixempra, Epothilone-B, epothilone B lactam, BMS-247550, Azaepothilone B	Microtubule stabilizer/mitotic inhibitor

NCT02587598

Advanced solid tumors (in expansion)

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

View Drugs

Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Azacytidine	azacitidine, Vidaza, Mylosar, 5-AZC	DNA methylation inhibitor
INCB053914	pan-PIM inhibitor INCB053914	PIM1, 2, 3 inhibitor

NCT02920996

Advanced solid tumors with NTRK1-3 rearrangements

A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements

View Drugs

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Merestinib	c-Met inhibitor LY2801653, LY2801653	Multi-targeted RTK inhibitor

NCT03113487

Platinum resistant ovarian cancer

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

View Drugs

California

Drug(s) in Trial	Other Drug Names	Main Known Action
p53MVA	Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53	Immune response against p53 tumor antigen
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT03212274

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

View Drugs

California, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor

NCT03253679

Advanced solid tumors with CCNE1 AMP

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

View Drugs

California, Colorado, District of Columbia, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor

NCT03146663

Platinum resistant high grade serous or endometrioid ovarian cancer (at least 3 prior therapies)

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

View Drugs

Arizona, California, Colorado, Florida, Illinois, Minnesota, Missouri, Tennessee, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
NUC-1031	gemcitabine ProTide, Acelarin, gemcitabine-phosphoramidate NUC-1031	Ribonucleotide reductase and DNA synthesis inhibitor

NCT03284385

Advanced solid tumors with SETD2 deficiency

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

View Drugs

California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor

NCT03274661

Advanced solid tumors

Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency

View Drugs

Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT03428802

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

View Drugs

New Jersey

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT03147976

Advanced solid tumors with MET over-expression or mutation

A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations

View Drugs

California

Drug(s) in Trial	Other Drug Names	Main Known Action
AMG 337		c-Met kinase inhibitor

NCT03395080

Platinum resistant or refractory ovarian cancer, or carcinosarcoma at first recurrence

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma

View Drugs

Alabama, Arizona, Florida, Illinois, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
DKN-01	DKK1-neutralizing monoclonal antibody DKN-01	Dickkopf-1 (DKK1) antagonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT03310879

Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

View Drugs

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor

NCT03355976

Recurrent clear cell ovarian cancer

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

View Drugs

Rhode Island

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT03462342

Recurrent ovarian cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

View Drugs

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Ceralasertib	AZD6738	ATR kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

NCT01876511

Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

View Drugs

California, Maryland, New York, Ohio, Oregon, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT03412877

Advanced solid tumors

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

View Drugs

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
TCR-transduced PBL		Anti-tumor immune response

NCT03570619

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

View Drugs

Florida, Michigan, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT03565991

Advanced solid tumors with BRCA1/2 or ATM mutations

A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors

View Drugs

California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor

NCT03579316

Recurrent ovarian cancer (PD on or after prior PARP inhibitor)

A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition

View Drugs

Massachusetts, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

NCT03610490

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

View Drugs

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response

NCT03651271

Recurrent ovarian cancer with high MSI

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

View Drugs

California, Massachusetts, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT03668119

Advanced solid tumors with high TMB

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

View Drugs

California, Colorado, Illinois, Minnesota, New York, North Carolina, Oregon, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

NCT03587311

Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

View Drugs

Missouri, Ohio, Tennesse